DOCSLIB.ORG

CAR T Cell Therapy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CAR T Cell Therapy CAR T Cell Therapy CAR T Cell Therapy Chimeric Antigen Receptor T cell therapy, or CAR T cell therapy, is an immunotherapy approach to treat cancer. CAR T Cell Therapy Production The production of CAR T cell therapy involves a number of steps.1,2 T cells, a type of white blood The collected T cells are then sent CAR T cells are multiplied in the CAR T cells are intended to recognize cell, are collected from to a laboratory where they are lab and infused into the patient’s and kill the cancerous cells that have a patient or a donor’s blood. engineered to produce chimeric bloodstream. the targeted antigen on their surface antigen receptors (CARs) on their while also continuing to multiply surface. The engineered T cells are within the body. now called CAR T cells. T cell Normal T cell CAR T cell Tumor CARs Approaches to CAR T Cell Therapy Development There are two approaches to the production of CAR T cell therapy. More research is needed to better understand the potential benefits and disadvantages of each approach. Allogeneic Autologous Allogeneic CAR T cells are engineered using T cells from a single Autologous CAR T cells are engineered donor that are utilized in multiple patients. using a patient’s own T cells. Healthy donor CAR T cells Patients Patient CAR T cells Pfizer is Actively Pursuing Allogeneic CAR T Cell Therapy Through collaborations with Cellectis and Servier, Pfizer is actively investigating allogeneic CAR T cell therapies across several targets. Cellectis’s CAR T platform technology provides a proprietary, allogeneic approach to developing CAR T cell therapies that seeks to make genetically-engineered immunotherapy treatments that could potentially be used by multiple patients. The collaboration with Servier enables us to co-develop and potentially commercialize UCART19, an investigational allogeneic CAR T cell therapy. 1 Chimeric Antigen Receptor (CAR) T-Cell Therapy. Leukemia and Lymphoma Society. Available at https://www.lls.org/treatment/types-of-treatment/immunotherapy/chimeric-antigen-receptor-car-t-cell-therapy. Accessed on February 10, 2016. 2 National Cancer Institute. CAR T-Cell Therapy: Engineering Patients’ Immune Cells to Treat Their Cancers. Available at: http://www.cancer.gov/about-cancer/treatment/research/car-t-cells. Accessed on February 10, 2016. May 2016 CCR2 Antagonist PF‐04136309 CCR2 Inhibitor PF‐04136309 (PF-6309) is an investigational small-molecule antagonist of the human chemokine (C‐C motif) receptor 2 (CCR2) – a type of receptor that binds to cytokines (proteins that are involved in cell signaling).1,2 PF-6309 Mechanism of Action CCL2 is a chemoattractant that is released by tumor cells and binds to CCR2, which is expressed on the surface of monocytes (types of white blood cells) in the bone marrow. CLL2 is thought to play a role in the recruitment of monocytes from the bone marrow to the tumors, where these cells then become tumor associated macrophages (TAM). They in turn, have been observed to limit the effectiveness of anti-tumor immune responses, leading to tumor progression and chemoresistance.3 PF-6309 binds to CCR2 and has been observed to inhibit the binding of CCL2 to its receptor CCR2. The inhibition of CCR2 is thought to stop the recruitment of monocytes and reverse immune suppression within the tumor microenvironment.3,4,5 CCR2-CCL2 Pathway CCR2 Inhibition tumor tumor PF-6309 CCR2 bind CCR2 MCP-1/ MCP-1/ CCL2 CCL2 monocyt e monocyt e monocyte The Potential of CCR2 Inhibition Studies suggest that inhibition of CCR2 may have application in a variety of diseases, including cancer. Pre-clinical studies of PF‐6309 show anti-tumor activity in localized pancreatic cancer. PF-6309 has also been evaluated in an investigator initated Phase 1b dose escalation study in pancreatic cancer. More research is needed to fully understand the potential of CCR2 inhibition in cancer and identify potential immunotherapy combinations. Clinical Study PF‐6309 is currently being studied in a Phase 1b/2 trial (dose escalation study followed by randomized Phase 2) for pancreatic cancer (NCT02732938).6 1. Zimmermann, W. et al. CCR1 and CCR2 Antagonists. Current Topics in Medicinal Chemistry 2014, 1539-1552. Available at: http://www.ingentaconnect.com/content/ben/ctmc/2014/00000014/00000013/art00005. Accessed April 13, 2016. 2. Miami Cancer Institute. Drug Dictionary. Available at: http://miamicancer.com/drug-dictionary/category/C/. Accessed April 13, 2016. 3. Nywening, T., et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non- randomised, phase 1b trial. The Lancet. 2016. http://dx.doi.org/10.1016/S1470-2045(16)00078-4. 4. Wang-Gillam, A., et al. Phase IB study of FOLFIRINOX plus PF-04136309 in patients with borderline resectable and locally advanced pancreatic adenocarcinoma (PC). Available at: http://meetinglibrary.asco.org/content/140478-158. Accessed April 13, 2016. 5. Deshmane, SL., et al. Monocyte Chemoattractant Protein-1 (MCP-1): An Overview. Journal of Interferon & Cytokine Research. 2009;29(6):313-326. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2755091/. Accessed April 13, 2016. 6. Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients (CCR2i). Available at: https://clinicaltrials.gov/ct2/show/NCT02732938?term=PF%E2%80%9004136309&rank=2. Accessed April 13, 2016. PF-6309 is an investigational compound. For more information, please visit www.pfizercancertrials.com or www.clinicaltrials.gov or call toll-free 1-877-369-9753 (in the United States and Canada) or +1-646-277-4066 (outside of the United States and Canada). May 2016 4-1BB AGONIST UTOMILUMAB (PF-05082566) Utomilumab is the proposed non-proprietary name for PF-05082566, an investigational immunotherapy and fully humanized monoclonalThe 4-1BB antibody(CD-137) protein (mAb) receptor administered is found intravenously on CD8+ and CD4+ that stimulatesT cells and natural signaling killer throughcells.1,2 Based 4-1BB on (CD-137), pre-clinical data, when utomilumab binds to 4-1BB,a itprotein stimulates expressed and increases in many the number immune of immunecells. cells.1 This may provide enhanced anti-tumor immune function.1 This is different from checkpoint inhibitors (i.e. PD-1, PD-L1), which act on another immune signaling pathway and are believed to work by inhibiting suppression of T cells.3 Mechanism of Action The 4-1BB (CD-137) protein receptor is found on CD8+ and CD4+ T cells and natural killer cells.1,2 Based on pre-clinical data, when CD8+ 1,2 utomilumabThe binds 4-1BB to 4-1BB, (CD-137) it stimulates protein and receptor increases is thefound number on CD8+ of immune and cells. CD4+Utomilumab1 This T cellsmay provideand natural enhanced killer anti-tumor cells. immune Activation 1 function.Based on This pre-clinical is different data,from checkpoint when utomilumab inhibitors (i.e. (PF-05082566) PD-1, PD-L1), which binds act to on 4-1BB, another it immune has been signaling observed pathway to andstimulateTumor are believed and increase the number of immuneto workcells. by1 This inhibiting may suppression provide enhanced of T cells.3 anti-tumor immune function.1 4-1BB Receptor NK CD8+ Utomilumab T cell Activation CD4+ Tumor Proliferation 4-1BB Receptor NK T cell CD4+ Proliferation The Potential of Combination Approach Preclinical studies suggest that combining utomilumab (PF-05082566) with a checkpoint inhibitor, such as anti-PD-L1, or other immunotherapiesPreclinical studies may suggest be able that combiningto amplify utomilumab the immune with a checkpointresponse. inhibitor,4,5,6 Further such as understandinganti-PD-L1, or other the immunotherapies biology of how may be able to amplify the immune response.4,5,6 Further understanding the biology of how the immune system attacks tumors and ways by which tumors the immune system attacks tumors andevade ways the by immune which tumors system evademay lead the to immune a variety system of promising may leadcombinations to new investigational in the future. compounds. Pfizer is exploringPfizer the is potentialexploring of the utomilumab potential of(PF-05082566) utomilumab in in a a clinical clinical developmentdevelopment program program to to determine: determine: Preclinical studiesCLINICAL suggest that combining utomilumab with a checkpoint inhibitor, such as anti-PD-L1, or other immunotherapies may be able CLINICALto amplify the immune • maximum response.4,5,6 tolerated Further• maximum understanding dose tolerated thedose biology of how the immune system attacks tumors and ways by which tumors STUDIES• anti-tumorevade the activity immune• efficacy andsystem safety may profilelead to a variety of promising combinations in the future. STUDIES • therapeutic potential in combination with other therapies • therapeutic potential in combination with other therapies Pfizer is exploring the potential of utomilumab in a clinical development program to determine: CLINICALPhase 1• maximum tolerated dose Future studies PhaseSTUDIES 1Data from a Phase• efficacy 1 study that evaluated utomilumab in Future studiesPfizer will further explore utomilumab in order to better combination •with therapeutic rituximab potential in patients in combination with relapsed with or other therapies understand its efficacy and safety when used as both a single Data from a refractoryPhase 1 CD20+ study thatnon-Hodgkin’s evaluated lymphoma utomilumab (NHL) showed
Load more

Recommended publications
  • Human Nerual Stem Cells for Brain Repair
    International Journal of Stem Cells Vol. 1, No. 1, 2008 REVIEW ARTICLE Human Nerual Stem Cells for Brain Repair Seung U. Kim1,2, Hong J. Lee1, In H. Park1, Kon Chu3, Soon T. Lee3, Manho Kim3, Jae K. Roh3, Seung K. Kim4, Kyu C. Wang4 1Institute for Regenerative Medicine, Gachon Medical University Gil Hospital, Incheon, Korea, 2Division of Neurology, Department of Medicine, UBC Hospital, University of British Columbia, Vancouver, Canada, Departments of 3Neurology and 4Neurosurgery, Seoul National University Hospital, Seoul, Korea Cell replacement therapy and gene transfer to the diseased or injured brain have provided the basis for the development of potentially powerful new therapeutic strategies for a broad spectrum of human neurological diseases including Parkinson disease, Huntington disease, amyotrophic lateral sclerosis (ALS), Alzheimer disease, multiple sclerosis (MS), stroke, spinal cord injury and brain cancer. In recent years, neurons and glial cells have successfully been generated from neural stem cells, and extensive efforts by investigators to develop neural stem cell-based transplantation therapies have been carried out. We review here notable experimental and pre-clinical studies we have previously conducted involving human neural stem cell-based cell- and gene-therapies for Parkinson disease, Huntington disease, ALS, stroke and brain cancer. Keywords: Stem cell, Human neural stem cell, Cell therapy, Gene transfer, Transplantation, Neurodegenrative diseases, Parkinson disease, Huntington disease, Amyotrophic lateral sclerosis, Stroke, Brain cancer neural stem cells (NSCs) could be isolated from various Introduction tissues. Existence of multipotent NSCs has been known in developing or adult rodent or human brain with proper- Stem cells are the cells that have the ability to renew ties of indefinite growth and multipotent potential to dif- themselves continuously and possess pluripotent ability to ferentiate into three major cell types of CNS, neurons, as- differentiate into many cell types.
    [Show full text]
  • Effects of Chemotherapy Agents on Circulating Leukocyte Populations: Potential Implications for the Success of CAR-T Cell Therapies
    cancers Review Effects of Chemotherapy Agents on Circulating Leukocyte Populations: Potential Implications for the Success of CAR-T Cell Therapies Nga T. H. Truong 1, Tessa Gargett 1,2,3, Michael P. Brown 1,2,3,† and Lisa M. Ebert 1,2,3,*,† 1 Translational Oncology Laboratory, Centre for Cancer Biology, University of South Australia and SA Pathology, North Terrace, Adelaide, SA 5000, Australia; [email protected] (N.T.H.T.); [email protected] (T.G.); [email protected] (M.P.B.) 2 Cancer Clinical Trials Unit, Royal Adelaide Hospital, Port Rd, Adelaide, SA 5000, Australia 3 Adelaide Medical School, University of Adelaide, North Terrace, Adelaide, SA 5000, Australia * Correspondence: [email protected] † These authors contributed equally. Simple Summary: CAR-T cell therapy is a new approach to cancer treatment that is based on manipulating a patient’s own T cells such that they become able to seek and destroy cancer cells in a highly specific manner. This approach is showing remarkable efficacy in treating some types of blood cancers but so far has been much less effective against solid cancers. Here, we review the diverse effects of chemotherapy agents on circulating leukocyte populations and find that, despite some negative effects over the short term, chemotherapy can favourably modulate the immune systems of cancer patients over the longer term. Since blood is the starting material for CAR-T cell Citation: Truong, N.T.H.; Gargett, T.; production, we propose that these effects could significantly influence the success of manufacturing, Brown, M.P.; Ebert, L.M.
    [Show full text]
  • Applications of Mesenchymal Stem Cells in Skin Regeneration and Rejuvenation
    International Journal of Molecular Sciences Review Applications of Mesenchymal Stem Cells in Skin Regeneration and Rejuvenation Hantae Jo 1,† , Sofia Brito 1,†, Byeong Mun Kwak 2,3,† , Sangkyu Park 4,* , Mi-Gi Lee 5,* and Bum-Ho Bin 1,4,* 1 Department of Applied Biotechnology, Ajou University, Suwon 16499, Korea; [email protected] (H.J.); sofi[email protected] (S.B.) 2 Department of Meridian and Acupoint, College of Korean Medicine, Semyung University, Chungbuk 27136, Korea; [email protected] 3 School of Cosmetic Science and Beauty Biotechnology, Semyung University, 65 Semyung-ro, Jecheon-si, Chungcheongbuk-do 27136, Korea 4 Department of Biological Sciences, Ajou University, Suwon 16499, Korea 5 Bio-Center, Gyeonggido Business and Science Accelerator, Suwon 16229, Korea * Correspondence: [email protected] (S.P.); [email protected] (M.-G.L.); [email protected] (B.-H.B.); Tel.: +82-31-219-2967 (S.P.); +82-31-888-6952 (M.-G.L.); +82-031-219-2816 (B.-H.B.) † These authors contributed equally to this study. Abstract: Mesenchymal stem cells (MSCs) are multipotent stem cells derived from adult stem cells. Primary MSCs can be obtained from diverse sources, including bone marrow, adipose tissue, and umbilical cord blood. Recently, MSCs have been recognized as therapeutic agents for skin regeneration and rejuvenation. The skin can be damaged by wounds, caused by cutting or breaking of the tissue, and burns. Moreover, skin aging is a process that occurs naturally but can be worsened by environmental pollution, exposure to ultraviolet radiation, alcohol consumption, tobacco use, and undernourishment. MSCs have healing capacities that can be applied in damaged and aged Citation: Jo, H.; Brito, S.; Kwak, B.M.; Park, S.; Lee, M.-G.; Bin, B.-H.
    [Show full text]
  • Cellular Therapy Brochure
    IMAGINE … better treatments. superior outcomes. a cure. We can. Center for Stem Cell and Cell Therapy Research. The Campaign for a Center for Stem Cell and Cell Therapy Research “We can’t wait. Patients continue to die from diseases we should be able to treat with cell therapy. We need to speed our pace of discovery to move these treatments forward so that more patients can receive – and be saved by – these cutting-edge treatments.” – Gilbert C. White, II, MD, Ambassador for Versiti Blood Research and Director Emeritus Your gift will make this a reality. An investment in our research will facilitate the hiring of 10 new investigators, the creation of new laboratories, and the advancement of research breakthroughs. Philanthropy will allow us to continue the exceptional work that we do – advancing into the forefront of stem cell and cell therapy research. “An investment in the Blood Research Institute is one of the best investments I can make in this community. The extraordinary work of the researchers who will make up this Center for Stem Cell and Cell Therapy Research will ensure we are at the forefront of cellular therapy – which is the future of health and medicine. With the crucial support of the philanthropic community, we will transform healthcare globally.” – John J. Stollenwerk, Co-Chair for the 2018 Imagine Gala, supporting the Blood Research Foundation Mitch Arnold Approximately every 9 minutes, someone in the U.S. dies from a blood cancer. – Leukemia and Lymphoma Society Stroke accounts for 1 in 19 deaths in the U.S. – United States Centers for Disease Control and Prevention Cancer is the second-most common cause of death among children ages 1-14 years in the U.S., after accidents.
    [Show full text]
  • Chimeric Antigen Receptor (CAR) T-Cell Therapy Facts
    Chimeric Antigen Receptor (CAR) T-Cell Therapy Facts LLSC: providing the latest information for patients, caregivers and healthcare professionals Introduction Surgery, chemotherapy, and radiation therapy have been The most frequently targeted antigen (any substance that the foundation of cancer treatment. Advances in the field causes the immune system to produce antibodies against it) of immunology (a branch of science that studies all aspects in CAR T-cell clinical trials for leukemia and lymphoma is called of the immune system) have led to a greater understanding “cluster of differentiation (CD) 19.” CAR T-cell trials targeting of the ways in which the body’s own defenses can be used other antigens (BCMA, CD22, CD123, ROR-1, NKG2D ligands) to improve outcomes and lessen some of the toxic side are also under way. CD19 is expressed on the surface of effects of treatment for patients with blood cancers. nearly all healthy and cancerous B cells, including lymphoma Cancer researchers are now studying how harnessing the and leukemia B cells. Because CD19 is not expressed on any immune system can help destroy cancer cells. healthy cells, other than B cells, it is an ideal target for CAR T-cell immunotherapy. The immune system is the body’s defense against infection and cancer. It is made up of billions of cells that are divided Chimeric Antigen Receptor T-Cell into several different types. Lymphocytes, one type of white Therapy: How it Works blood cell, comprise a major portion of the immune system. There are three types of lymphocytes: B lymphocytes (B cells), T lymphocytes (T cells) and natural killer (NK) cells.
    [Show full text]
  • Chimeric Antigen Receptor T-Cell (Car-T) Therapy
    Mandala 10:00 Team 22 Disclaimer: This paper partially fulfills a writing requirement for first-year (freshmen) engineering students at the University of Pittsburgh Swanson School of Engineering. This paper is a student paper, not a professional paper. This paper is not intended for publication or public circulation. This paper is based on publicly available information, and while this paper might contain the names of actual companies, products, and people, it cannot and does not contain all relevant information/data or analyses related to companies, products, and people named. All conclusions drawn by the authors are the opinions of the authors, first-year (freshmen) students completing this paper to fulfill a university writing requirement. If this paper or the information therein is used for any purpose other than the authors' partial fulfillment of a writing requirement for first-year (freshmen) engineering students at the University of Pittsburgh Swanson School of Engineering, the users are doing so at their own--not at the students', at the Swanson School's, or at the University of Pittsburgh's--risk. NEW TECHNOLOGY IN CANCER THERAPY: CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY Chance Brooks [email protected], Sophie Napolitano [email protected], Victoria Turchick [email protected] Abstract– Our paper will explore the process and coining of Hodgkin’s disease – and the more prevalent applications of Chimeric Antigen Receptor T-cell (CAR-T) variation, non-Hodgkin’s lymphoma – in the mid-18th Therapy. T-cells are one of the most important cell types in century. Despite this early discovery, it took another eighty the human body’s immune system due to their ability to years for treatment to become widespread after World War identify and destroy threatening foreign cells in the body.
    [Show full text]
  • Cellular Therapy Products
    Cellular Therapy Products SLIDE 1 This presentation will discuss the regulation of cellular therapies. SLIDE 2 Manufacturing of cellular therapies is reviewed in the Division of Cell and Gene Therapies in the Office of Cellular, Tissue and Gene Therapies. This slide shows the organizational chart for the Division of Cell and Gene Therapies. The division consists of two product review branches: gene therapy and cell therapy. The division also has three branches that conduct laboratory research, as well as product review. They are the gene transfer and immunogenicity branch, tumor vaccines and biotechnology branch, and the cellular and tissue therapy branch. SLIDE 3 Somatic cell therapies are regulated as biologics under the Public Health Service Act section 351, in contrast to human tissues, which are regulated under section 361, where the primary safety concern is infectious disease transmission. Human cells are regulated as biologics if any of the following criteria are met: they are more than minimally manipulated, they are combined with another article other than a preservation or storage agent, they are used in a way that is not homologous to their normal function, or they have a systemic effect and are dependent upon the metabolic activity of living cells for their primary function. These criteria are sometimes referred to as kick-up factors, meaning that FDA regulated clinical development under Investigational New Drug, or IND, and premarket approval will be required for human cells that meet any one of these criteria. SLIDE 4 The kick-up factors on the previous slide coincide with the FDA definition of somatic cell therapy that was first published by the agency in 1993.
    [Show full text]
  • Orthopedic Applications of Stem Cell Therapy
    Corporate Medical Policy Orthopedic Applications of Stem Cell Therapy File Name: orthopedic_applications_of_stem_cell_therapy Origination: 7/2010 Last CAP Review: 2/2021 Next CAP Review: 2/2022 Last Review: 2/2021 Description of Procedure or Service Mesenchymal stem cells (MSCs) have the capability to differentiate into a variety of tissue types, including various musculoskeletal tissues. Potential uses of MSCs for orthopedic applications include treatment of damaged bone, cartilage, ligaments, tendons and intervertebral discs. Background MSCs are multipotent cells (also called multipotent stromal cells) that possess the ability to differentiate into various tissues including organs, trabecular bone, tendon, articular cartilage, ligaments, muscle and fat. MSCs are associated with the blood vessels within bone marrow, synovium, fat, and muscle, where they can be mobilized for endogenous repair as occurs with healing of bone fractures. Tissues such as muscle, cartilage, tendon, ligaments, and vertebral discs show limited capacity for endogenous repair because of the limited presence of the triad of tissue functional components: vasculature, nerves, and lymphatics. Orthobiologics is a term introduced to describe interventions using cells and biomaterials to support healing and repair. Cell therapy is the application of MSCs directly to a musculoskeletal site. Tissue engineering techniques use MSCs and/or bioactive molecules such as growth factors and scaffold combinations to improve the efficiency of repair or regeneration of damaged musculoskeletal tissues. Bone marrow aspirate is considered to be the most accessible source and thus the most common place to isolate MSCs for treatment of musculoskeletal disease. However, harvesting MSCs from bone marrow requires an additional procedure that may result in donor site morbidity.
    [Show full text]
  • CAR T-Cell Therapy for Acute Lymphoblastic Leukemia
    The Science Journal of the Lander College of Arts and Sciences Volume 12 Number 2 Spring 2019 - 2019 CAR T-cell Therapy for Acute Lymphoblastic Leukemia Esther Langner Touro College Follow this and additional works at: https://touroscholar.touro.edu/sjlcas Part of the Biology Commons, and the Pharmacology, Toxicology and Environmental Health Commons Recommended Citation Langner, E. (2019). CAR T-cell Therapy for Acute Lymphoblastic Leukemia. The Science Journal of the Lander College of Arts and Sciences, 12(2). Retrieved from https://touroscholar.touro.edu/sjlcas/vol12/ iss2/6 This Article is brought to you for free and open access by the Lander College of Arts and Sciences at Touro Scholar. It has been accepted for inclusion in The Science Journal of the Lander College of Arts and Sciences by an authorized editor of Touro Scholar. For more information, please contact [email protected]. CAR T-cell Therapy for Acute Lymphoblastic Leukemia Esther Langner Esther Langner will graduate in June 2019 with a Bachelor of Science degree in Biology and will be attending Mercy College’s Physician Assistant program. Abstract Despite all the available therapies, Acute Lymphoblastic Leukemia (ALL) remains extremely difficult to eradicate. Current available therapies, which include chemotherapy, radiation, and stem cell transplants, tend to be more successful in treating children than adults .While adults are more likely than children to relapse after treatment, the most common cause of treatment failure in children is also relapse. Improved outcomes for all ALL patients may depend upon new immunotherapies, specifically CAR T-cell therapy. CAR T-cell therapy extracts a patient’s own T-cells and modifies them with a CD19 antigen.
    [Show full text]
  • Xenogeneic and Stem Cell-Based Therapy for Cardiovascular Diseases: Genetic Engineering of Porcine Cells and Their Applications in Heart Regeneration
    International Journal of Molecular Sciences Review Xenogeneic and Stem Cell-Based Therapy for Cardiovascular Diseases: Genetic Engineering of Porcine Cells and Their Applications in Heart Regeneration Anne-Marie Galow 1,* , Tom Goldammer 1,2 and Andreas Hoeflich 1 1 Institute of Genome Biology, Leibniz Institute for Farm Animal Biology, 18196 Dummerstorf, Germany; [email protected] (T.G.); hoefl[email protected] (A.H.) 2 Molecular Biology and Fish Genetics Unit, Faculty of Agriculture and Environmental Sciences, University of Rostock, 18059 Rostock, Germany * Correspondence: [email protected]; Tel.: +49-38208-68-723 Received: 18 November 2020; Accepted: 15 December 2020; Published: 18 December 2020 Abstract: Cardiovascular diseases represent a major health concern worldwide with few therapy options for ischemic injuries due to the limited regeneration potential of affected cardiomyocytes. Innovative cell replacement approaches could facilitate efficient regenerative therapy. However, despite extensive attempts to expand primary human cells in vitro, present technological limitations and the lack of human donors have so far prevented their broad clinical use. Cell xenotransplantation might provide an ethically acceptable unlimited source for cell replacement therapies and bridge the gap between waiting recipients and available donors. Pigs are considered the most suitable candidates as a source for xenogeneic cells and tissues due to their anatomical and physiological similarities with humans. The potential of porcine cells in the field of stem cell-based therapy and regenerative medicine is under intensive investigation. This review outlines the current progress and highlights the most promising approaches in xenogeneic cell therapy with a focus on the cardiovascular system. Keywords: cell transplantation; myocardial infarction; mesenchymal stem cells; graft rejection; triple knockout pigs; genome editing; iPSCs; CRISPR/Cas 1.
    [Show full text]
  • Instant Stem Cell Therapy: Characterization and Concentration of Human Mesenchymal Stem Cells in Vitro
    PEuropean Kasten et Cells al. and Materials Vol. 16 2008 (pages 47-55) DOI: 10.22203/eCM.v016a06 In stant stemISSN cell 1473-2262 therapy INSTANT STEM CELL THERAPY: CHARACTERIZATION AND CONCENTRATION OF HUMAN MESENCHYMAL STEM CELLS IN VITRO P. Kasten1*, I. Beyen1, M. Egermann1, A.J. Suda1, A.A. Moghaddam2, G. Zimmermann2, R. Luginbühl3 1 Orthopaedic Surgery Hospital, University of Heidelberg, Schlierbacher Landstr. 200a, D-69118 Heidelberg, Germany 2 Trauma Center Ludwigshafen, Ludwigshafen, Germany, 3 Dr. hc Robert Mathys Foundation, Bettlach, Switzerland Abstract Introduction In regenerative medicine, there is an approach to avoid The use of mesenchymal stem cells (MSC) is the principal expansion of the mesenchymal stem cell (MSC) before part of the tissue engineering approach to regenerate tissue implantation. The aim of this study was to compare methods defects. MSC are contained in bone marrow (BM) for instant MSC therapy by use of a portable, automatic aspirates in a concentration of approximately 10-100 MSC and closed system centrifuge that allows for the per 1x106 BM cells (Bruder et al., 1994; Campagnoli et concentration of MSCs. The main outcome measures were al., 2001; Hernigou et al., 2005; Prockop et al., 2000; the amount of MSCs per millilitre of bone marrow (BM), Wexler et al., 2003). For clinical use, e.g. to accelerate clusters of differentiation (CD), proliferation and bone healing, high cell numbers are needed depending differentiation capacities of the MSC. A volume reduction on the size of the bone defect (Bruder et al., 1998; Quarto protocol was compared to the traditional laboratory methods et al., 2001).
    [Show full text]
  • Stem Cell Therapy for Neurodegenerative Diseases
    Review Stem Cell Therapy for Neurodegenerative Diseases Hanyang Med Rev 2015;35:229-235 http://dx.doi.org/10.7599/hmr.2015.35.4.229 1 2,3 2,3 pISSN 1738-429X eISSN 2234-4446 Jong Zin Yee , Ki-Wook Oh , Seung Hyun Kim 1Hanyang University College of Medicine, Seoul, Korea 2Department of Neurology, Hanyang University College of Medicine, Seoul, Korea 3Cell Therapy Center for Neurologic Disorders, Hanyang University Hospital, Seoul, Korea Neurodegenerative diseases are the hereditary and sporadic conditions which are charac- Correspondence to: Seung Hyun Kim Department of Neurology, Hanyang terized by progressive neuronal degeneration. Neurodegenerative diseases are emerging University College of Medicine, as the leading cause of death, disabilities, and a socioeconomic burden due to an increase 222 Wangsimni-ro, Seongdong-gu, in life expectancy. There are many neurodegenerative diseases including Alzheimer’s dis- Seoul 04763, Korea Tel: +82-2-2290-8371 ease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s disease, and multiple Fax: +82-2-2296-8370 sclerosis, but we have no effective treatments or cures to halt the progression of any of E-mail: [email protected] these diseases. Stem cell-based therapy has become the alternative option to treat neuro- degenerative diseases. There are several types of stem cells utilized; embryonic stem cells, Received 4 September 2015 Revised 6 October 2015 induced pluripotent stem cells, and adult stem cell (mesenchymal stem cells and neural Accepted 13 October 2015 progenitor cells). In this review, we summarize recent advances in the treatments and the This is an Open Access article distributed under limitations of various stem cell technologies.
    [Show full text]